Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar
This article was originally published in PharmAsia News
MUMBAI - Becoming too big may have resulted in operational inefficiencies and deteriorating R&D output for global drug makers, but getting bigger may be a successful formula for branded generics businesses in emerging markets
You may also be interested in...
CASE STUDY: Can Novartis India Reboot Star Brand Voveran?
Faced with savvy competitor introductions and government price cuts, Voveran, a star painkiller brand from Novartis, is seeing unprecedented market challenges in India. Can it survive the onslaught and what is the company doing to revive the product?
Emerging Markets Survey Shows Limited Premium For International Drug Brands-Credit Suisse
A recent Credit Suisse report showed acceptability for global brands widely varied in emerging markets. While consumers did not show a great degree of trust for local pharmaceutical brands, the premium they are willing to pay for an international brand is also limited.
Closer Look: Sun-Ranbaxy A Powerhouse But Sales Culture A Dilemma?
The merger of Sun and Ranbaxy is seen as the most ideal combination to seize Indian market opportunities. But field force integration may pose a tough barrier as the two sides operate very different marketing strategies.